EBRO 2017

Neoadjuvant chemoradiation in esophageal cancer: CROSS trial

EBRO 2017

Neo-adjuvant chemoradiotherapy: 41.4 Gy + weekly Carboplatin AUC2 / Paclitaxel 50 mg/m 2 RESECTION

N=363

R A N D O M

T1N1M0 or T2-3N0-1M0

Primary endpoint: Overall survival

AC (75%) SCC (23%)

RESECTION

Van Hagen et al. NEJM 2012

Shapiro et al. Lancet Oncol 2015